According to an Aug. 10 press release, the district court ruled that some of Bausch’s patents for the drug Xifaxan were valid and infringed and other IBS-D patents were invalid. The other party involved in the case is Norwich Pharmaceuticals, which wants to bring a generic version of Xifaxan to the market.
The company plans to appeal the decision to the U.S. Court of Appeals for the Federal Circuit and expects a ruling in 12 to 18 months.
